Cogstate (ASX:CGS) Tax Provision : A$0.59 Mil (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Cogstate Tax Provision?

Cogstate's tax provision for the six months ended in Dec. 2023 was A$-0.13 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.59 Mil.

Cogstate Tax Provision Historical Data

The historical data trend for Cogstate's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cogstate Tax Provision Chart

Cogstate Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Tax Provision

Get a 7-Day Free Trial

1.95

1.11

-0.77

-4.52

0.81

Cogstate Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Tax Provision	Get a 7-Day Free Trial															-2.84	-1.62	0.09	0.72	-0.13

Cogstate Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.59 Mil.

Cogstate (ASX:CGS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cogstate Ltd (ASX:CGS) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

COGZF:USA

Address

161 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cogstate.com

Cogstate Ltd is a cognitive science company. The principal activity of the company is the sale of technology and services for the measurement of cognition, where services include scientific consultancy, project management, data management, statistical analysis, and reporting. Its operating segment includes Clinical Trials; Healthcare and Research. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.

Cogstate (ASX:CGS) Headlines

No Headlines